ReviewDiscover oncology2026

Olverembatinib (HQP1351): a third-generation tyrosine kinase inhibitor in the treatment of hematologic and solid malignancies-a comprehensive review of clinical outcomes.

Sina Sadati et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.